KROS insider trading
NasdaqGM HealthcareKeros Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Company website: www.kerostx.com
KROS insider activity at a glance
FilingIQ has scored 512 insider transactions for KROS since Apr 13, 2020. The most recent filing in our index is dated Apr 15, 2026.
Across the full history, 37 open-market purchases
and 344 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on KROS insider trades is 54.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest KROS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading KROS
13F funds holding KROS
Frequently asked
- How many insider trades does FilingIQ track for KROS?
- FilingIQ tracks 512 Form 4 insider transactions for KROS (Keros Therapeutics, Inc.), covering filings from Apr 13, 2020 onwards. 16 of those were filed in the last 90 days.
- Are KROS insiders net buyers or net sellers?
- Across the full Form 4 history for KROS, 37 transactions (7%) were open-market purchases and 344 (67%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does KROS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is KROS in?
- Keros Therapeutics, Inc. (KROS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $493.55M.
Methodology & sources
Every KROS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.